[HMGB1 as a target for prevention of chemotherapy-induced peripheral neuropathy].

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) considerably impairs cancer patients' QOL, and may lead to discontinuation of drug treatment of cancer. Currently, there is no effective strategy against CIPN. Therefore, it is an urgent issue to develop clinically available drugs that prevent or treat CIPN. We have shown that high mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) molecule, plays an essential role in the development of CIPN. Most interestingly, thrombomodulin α, approved as a medicine for treatment of disseminated intravascular coagulation (DIC) in Japan, causes thrombin-dependent degradation of extracellular HMGB1 that is released in response to chemotherapeutics, and prevents CIPN. Thus, we expect that targeting HMGB1 or its receptors would lead to prevention of CIPN in cancer patients in near future.

• Authors: Atsufumi Kawabata, Maho Tsubota, Fumiko Sekiguchi, Ryuichi Tsujita
• Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica (Nihon Yakurigaku Zasshi) Vol. 154 Issue 5 Pg. 236-240 ( 2019) ISSN: 0015-5691 [Print] Japan
• PMID: 31735750 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• HMGB1 Protein
• Thrombomodulin

Topics

• Antineoplastic Agents (adverse effects)
• HMGB1 Protein
• Humans
• Japan
• Molecular Targeted Therapy
• Peripheral Nervous System Diseases (chemically induced, prevention & control)
• Thrombomodulin (therapeutic use)